Kiniksa Pharmaceuticals — Third Quarter 2026 Earnings Summary

Kiniksa Pharmaceuticals reported third-quarter 2026 net product revenue of $286.0 million for ARCALYST, representing approximately 58% year-over-year growth. The company raised its full-year 2026 ARCALYST net product revenue guidance to a range of $1.045 billion to $1.050 billion, up from the previous range of $980 million to $995 million. Total operating expenses for the quarter reached $231.7 million, driven by increased collaboration, research and development, and selling, general, and administrative costs associated with ARCALYST commercialization. Kiniksa expects to receive pivotal Phase 3 data for its investigational drug KPL-387 in the second half of 2027 and plans to initiate a Phase 1 trial for KPL-1161 by the end of 2026.